Boston, MA -- (SBWIRE) -- 01/02/2014 -- Compared with other second tier markets in Latin America, Peru's pharmaceutical market has generated the least interest among multinationals. Its low per capita spending on drugs, weakening currency, and local authorities' bias towards non-equivalent generic products all mean multinationals have an undesirable market position. However, as the Peruvian government has not established a comprehensive medicine pricing system, pharmaceutical companies can generate rapid sales growth, particularly from the country's out-of-pocket spending sector. In addition, Peru's investor-friendly business environment, healthcare sector investment and its ongoing liberalisation of bilateral trade arrangements will further reduce trade barriers for foreign companies.

View Full Report Details and Table of Contents

Headline Expenditure Projections

- Pharmaceuticals: PEN4.11bn (US$1.56bn) in 2012 to PEN4.38bn (US$1.62bn) in 2013; +6.6% in local currency terms and +3.8% in US dollar terms. Local currency forecast broadly in line with Q4 2013 projection.
- Healthcare: PEN25.78bn (US$9.77bn) in 2012 to PEN27.76bn (US$10.24bn) in 2013; +7.7% in local currency terms and +4.8% in US dollar terms. Local currency forecast broadly in line with Q4 2013 projection.

Risk/Reward Rating: In BMI's RRRs for Q1 2014, Peru remains 10th out of the 18 markets surveyed in the Americas matrix. Peru's Reward and Risk scores are both viewed as being less favourable than the regional averages. A small market size and a deficient IP environment are some of the major drawbacks to the involvement of foreign companies in Peru. Nevertheless, Peru is still seen as being able to offer longer-term benefits to foreign investors, on account of the expected healthcare market development and economic growth.

Key Trends And Developments

- In August 2013, Japanese major Takeda launched a wholly owned subsidiary in Peru following its market expansion in other Latin American countries, such as Brazil, Mexico, Argentina, Venezuela, Colombia and Ecuador. According to Norbert Oppitz, senior vice-president of Takeda Latin America: 'This investment further demonstrates our commitment to Latin America and its growth potential.' In line with Takeda's emerging markets strategy, Takeda Peru is building a product portfolio tailored to local needs, such as treatments for gastroenterology, cardiology, metabolism, oncology and respiratory diseases. In addition to its established presence in other regional markets, we also expect Takeda to be successful in Peru's drug market, in part due to the strong historic/diplomatic ties between Peru and Japan.

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Healthcare research reports at Fast Market Research

You may also be interested in these related reports:

- Sweden Pharmaceuticals & Healthcare Report Q1 2014
- Bulgaria Pharmaceuticals & Healthcare Report Q1 2014
- Nigeria Pharmaceuticals & Healthcare Report Q1 2014
- Romania Pharmaceuticals & Healthcare Report Q1 2014
- Oman Pharmaceuticals & Healthcare Report Q1 2014
- Uzbekistan Pharmaceuticals & Healthcare Report Q1 2014
- Slovenia Pharmaceuticals & Healthcare Report Q1 2014
- Croatia Pharmaceuticals & Healthcare Report Q1 2014
- Latvia Pharmaceuticals & Healthcare Report Q1 2014
- Netherlands Pharmaceuticals & Healthcare Report Q1 2014